When the FDA takes action against developers of diagnostic tests, it seems to come primarily during times when new tests are desperately needed. Will Rinehart of the Center for Growth and Opportunity discusses the problem.
CGO scholars and fellows frequently comment on a variety of topics for the popular press. The views expressed therein are those of the authors and do not necessarily reflect the views of the Center for Growth and Opportunity or the views of Utah State University.
Policy Commons